Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for ipratropium
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ipratropium or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on ipratropium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Nebulized ipratropium bromide in acute pediatric asthma: Does it reduce hospital admissions among children presenting to the emergency department? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.
Effect of nebulized ipratropium on the hospitalization rates of children with asthma. 9761804 1998 10 08 1998 10 08 2013 11 21 0028-4793 339 15 1998 Oct 08 The New England journal of medicine N. Engl. J. Med. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. 1030-5 Anticholinergic medications such as ipratropium improve the pulmonary function of patients with acute exacerbations of asthma, but their effect on hospitalization rates is uncertain. We conducted (...) received 500 microg (2.5 ml) of ipratropium bromide with the second and third doses of albuterol; children in the control group received 2.5 ml of normal saline at these times. Overall, the rate of hospitalization was lower in the ipratropium group (59 of 215 children [27.4 percent]) than in the control group (80 of 219 [36.5 percent], P=0.05). For patients with moderate asthma (indicated by a peak expiratory flow rate of 50 to 70 percent of the predicted value or an asthma score of 8 to 11 on a 15
Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis Osmond M H, Klassen T P Authors' objectives To establish if ipratropium bromide, when given in conjunction with beta2-agonists, is beneficial to the health of children suffering with acute asthma. Searching MEDLINE was searched from 1966 to 1992 for articles published (...) , placebo-controlled trials were included. Specific interventions included in the review Inhaled ipratropium bromide and placebo in conjunction with inhaled beta2-agonists (fenoterol or salbutamol). Participants included in the review Children under 18 years who had an acute unprovoked asthma attack (by reasonable definition) were included. Outcomes assessed in the review Any of the following clinical or physiological outcomes were measured: change in vital signs, length of admission, peak expiratory
Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. 2567431 1989 07 21 1989 07 21 2015 06 16 0140-6736 1 8652 1989 Jun 24 Lancet (London, England) Lancet Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. 1418-20 103 patients with acute airflow obstruction (56 asthma, 47 chronic obstructive pulmonary disease [COPD]) completed a double-blind trial of nebulised bronchodilator treatment in a hospital accident (...) and emergency department. Each patient was randomised to receive either 10 mg of salbutamol nebuliser solution in 2 ml of saline or 10 mg of salbutamol in 2 ml (0.5 mg) of preservative-free ipratropium bromide. Peak flow rate (PFR) was recorded before treatment and 1 hour after beginning nebulised treatment. In 23 asthmatic patients given salbutamol alone PFR rose by a mean 31% 1 hour after treatment whereas in 33 such patients given combined treatment it rose by a mean 77% (95% confidence interval for the difference